ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients LA JOLLA, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces a report published in a high profile,...